1. Home
  2. SPT vs NGEN Comparison

SPT vs NGEN Comparison

Compare SPT & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPT

Sprout Social Inc

HOLD

Current Price

$5.54

Market Cap

327.6M

Sector

Technology

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$3.73

Market Cap

317.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SPT
NGEN
Founded
2010
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
327.6M
317.6M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
SPT
NGEN
Price
$5.54
$3.73
Analyst Decision
Buy
Analyst Count
8
0
Target Price
$12.38
N/A
AVG Volume (30 Days)
1.7M
101.3K
Earning Date
05-07-2026
04-02-2026
Dividend Yield
N/A
N/A
EPS Growth
32.11
N/A
EPS
N/A
N/A
Revenue
$457,547,000.00
N/A
Revenue This Year
$9.03
N/A
Revenue Next Year
$8.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.72
N/A
52 Week Low
$5.39
$3.51
52 Week High
$24.74
$5.93

Technical Indicators

Market Signals
Indicator
SPT
NGEN
Relative Strength Index (RSI) 34.76 38.60
Support Level N/A $3.69
Resistance Level $7.39 $4.44
Average True Range (ATR) 0.31 0.22
MACD 0.06 -0.01
Stochastic Oscillator 15.75 33.90

Price Performance

Historical Comparison
SPT
NGEN

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: